Alector’s Strategic Collaborations and Promising Developments Drive Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on ALEC stock, giving a Buy rating on September 15.

Myles Minter has given his Buy rating due to a combination of factors surrounding Alector’s promising developments and strategic collaborations. The company’s focus on the Phase III INFRONT-3 study for latozinemab in treating frontotemporal dementia associated with a GRN gene mutation is a significant factor. This study, conducted in partnership with GSK, is expected to provide pivotal data by the fourth quarter of 2025, which could potentially lead to a favorable risk/reward scenario for investors.
Alector’s readiness to proceed with regulatory filings following the INFRONT-3 data release further supports the Buy rating. The company’s proactive approach to addressing regulatory requirements, such as the addition of plasma progranulin as a co-primary endpoint, demonstrates its commitment to advancing its pipeline. Additionally, Alector’s strategic collaboration with GSK and its ability to rapidly complete necessary CMC activities underscore the potential for successful commercialization, enhancing the stock’s attractiveness.

In another report released on September 15, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.